VKTX Stock Recent News

According to Harvard University, about two-thirds of United States adults are “overweight or obese,” while 36% are obese. And the university predicts that, at the current rate, about 50% of Americans will be obese by 2030.

Viking Therapeutics has been one of the few standouts in healthcare this year. The company's experimental weight loss candidate has fueled a sharp uptick in its share price over the prior 13 months.

Viking Therapeutics is developing two highly promising medicines. If the company succeeds, its share price will skyrocket even more.

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Weight loss medications are fueling the pharmaceutical industry right now. One potential side effect of losing weight can be reductions in muscle mass -- which can pose serious health issues.

Viking aims to challenge big pharma players Eli Lilly and Novo Nordisk in the multibillion-dollar weight loss drug market. It recently reported excellent clinical trial results for its injectable and oral tablet weight loss candidates.

Upstart biotech Viking Therapeutics is hoping to enter the weight loss treatment market. The company has released encouraging data from clinical trials for its candidate, VK2735.